# Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

> **NCT03153410** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 11 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** GVAX Pancreas Vaccine (GVAX)
- **DRUG:** Pembrolizumab
- **DRUG:** IMC-CS4

## Key facts

- **NCT ID:** NCT03153410
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2022-03-09
- **Final completion:** 2023-08-29
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153410, "Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03153410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*